Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies

Table 4 Details of the 6 patients with inconsistency of dMMR and MSI-H

No.	Tumor location	Clinical stage	Heredity	MMR (IHC)biopsy	MMR (NGS) biopsy	MSI (PCR) biopsy	MSI (NGS) biopsy	MMR (IHC) surgery	MMR (NGS) surgery	MMR (PCR) surgery	MMR (NGS) surgery	Reason
6	Duodenum	T4aN+M0	Lynch	dMMR	dMMR	MSI-L	MSI-L					-
15	Colon	T4aN+M0	No	dMMR	pMMR	MSS	MSS	pMMR	pMMR	MSS	MSS	Tumor heterogeneity
20	Colon	T4aN2bM0	No	dMMR	dMMR	MSS	MSS	dMMR	dMMR	MSI-H	MSI-H	Low tumor content
21.	Colon	T3N2aM0	No	pMMR	dMMR	MSI-H	MSI-H					Only MSH3 mt
25	Rectum	T3N+M0	No	pMMR	pMMR	MSS	MSI-H	pMMR	pMMR	MSS	MSI-H	DDR mt
27	Rectum	T3N2M0	No	pMMR	pMMR	MSS	MSI-H					DDR mt

IHC: Immunohistochemistry; PCR: Polymerase chain reaction; NGS: Next-generation sequencing; MSH-L: Microsatellite instability-low; pMMR: Proficient mismatch repair; dMMR: Different mismatch repair; WT: Wild type; MT: Mutant type.